As the exact etiology of RAU is still unknown, therapy is based on symptomatic relief.

No abstract

Bullous pemphigoid is the most common of the blistering disorders. It is most commonly found in the elderly and is diagnosed based on clinical, histologic, and immunologic criteria. It presents clinically with diffuse eczematous, pruritic, urticaria-like lesions, with the later appearance of tense bullae or blistering lesions typically filled with clear fluid. Histologically, a sub-epidermal blister is seen and immunofluorescence shows immunoglobulin G antibodies directed against the structural components of the keratinocytic hemidesmosomal proteins BP180 and BP230. Multiple treatment modalities are present for this condition, including anti-inflammatory medications, medications that reduce antibody formation, and treatments to increase the elimination of antibodies. The aim of this case report is to present a classic case of this condition, to highlight an awareness of differing treatment options, and to advocate referral to a dermatologist given its potential severity.

Immune checkpoint inhibitors have advanced cancer treatment but commonly cause cutaneous immune-related adverse events, such as skin rash and pruritus. There is limited understanding on how to characterize cutaneous adverse events and their impact on healthrelated quality of life (HRQOL). This systematic review aimed to assess HRQOL outcome measures in studies of immune checkpoint inhibitors and identify if impact from cutaneous adverse events were specifically captured. A systematic literature search of PubMed, Embase, and Web of Science was performed using the following search terms: immune checkpoint inhibitors (avelumab, pembrolizumab, nivolumab, ipilimumab, atezolizumab, durvalumab) and quality of life. Human subject studies in English, including case series, cohorts, or randomized clinical trials, published in 1/2008e11/2018 were included. Among 1500 studies identified on initial screening, 23 studies (22 randomized controlled trials and 1 observational cohort) met inclusion criteria. Nivolumab (12 studies), ipilimumab (6 studies), and combined treatment with both nivolumab and ipilimumab (3 studies) were the most common therapies assessed. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) was used by 14 studies (61%) but did not contain any question related to the skin. Only 4 studies (17%) used questionnaires that included skinrelated questions: 2 used the Functional Assessment of Cancer Therapy-Melanoma (FACT-M), a melanoma-specific quality of life survey that asked about melanoma surgical site (swelling, pain) and overall skin appearance; 2 used the EORTC-QLQ-LC13, which included 1 question on alopecia. In comparison, 22 of 23 studies reported at least 1 cutaneous adverse event. As the use of immune checkpoint inhibitors becomes more widespread, rigorous assessment of the skin-and itch-specific HRQOL impact from immunotherapy will be critical. Medical marijuana is an emerging therapy in dermatology. Cannabinoids can be separated into endocannabinoids, phytocannabinoids, and synthetic cannabinoids. In this presentation, the experiences of a clinical group with over 150 dermatology patients treated with medical marijuana are reviewed, and encompass a variety of conditions, including but not limited to psoriasis, atopic dermatitis, and acne. The latest medical literature, including indications for medical marijuana, mechanisms of action, possible adverse effects and ethical dilemmas are also reviewed. In addition to the previously listed dermatological conditions, potential uses of marijuana in dermatology include skin cancer and seborrheic dermatitis. Treatment with medical marijuana has also been investigated in difficult to treat conditions such as scleroderma, pruritus, Kaposi Sarcoma and hidradenitis suppuritiva. Skin diseases cause recurrent symptoms, disfigurement and depression. Dermatologists routinely underestimate the impact of their patient's skin disease on quality of life (QoL). Patient-reported outcomes (PROs) are validated surveys...

SIRT7 is a crucial nuclear-located histone deacetylase with great implications in regulating genome stability, RNA metabolism and mitochondrial function, and its dysregulated expression and function are associated with the pathogenesis of multiple cancers. However, the role of SIRT7 in melanoma progression and the underlying mechanism are far from understood. In the present study, we first found that SIRT7 expression was prominently increased in both melanoma cell lines and tissues compared with controls. Moreover, the knockdown of SIRT7 significantly suppressed melanoma cell proliferation and colony formation, as well as potentiated oxidative stress or ER stress-induced cell apoptosis. Forwardly, we showed that SIRT7 positively regulated the expression of MITF, and MITF deficiency reversed the facilitative role of SIRT7 in promoting melanoma cell proliferation. The influence of SIRT7 on MITF expression was associated with its impact on TGF-b-SMAD4 pathway and subsequent mediation of PAX3 transcriptional function. Overall, our data demonstrated that up-regulated SIRT7 expression contributed to melanoma growth by promoting MITF expression, and targeting SIRT7 could be potent therapeutic approach for melanoma therapy.

No abstract

Human papillomavirus (HPV) is a widespread sexually transmitted infection which can lead to genital warts, squamous cell carcinoma, and verrucous carcinomas. Buschke-Loewenstein tumor (BLT) is a verrucous carcinoma which occurs in the anogenital and perianal areas. BLT is often associated with HPV 6 and 11, but HPV is preventable through routine vaccination. The Centers for Disease Control and Prevention (CDC) provides recommendations for routine HPV vaccination among both adolescents and adults. Following these guidelines may result in decreased incidence of BLT and minimize the need for subsequent invasive treatment. Here we present a case of BLT and advocate the use of HPV vaccination among patients to prevent discussed potential adverse outcomes.

No abstract